Alla Nemchenko, Viktoriya Nazarkina, Yuliia Kurylenko


The aim of the study is to develop a method for forecasting the indicators for drug reimbursement to patients with cardiovascular diseases (CVD) in Ukraine within the framework of the government program “Available medicines”.

Materials and methods: materials of the State Statistics Service of Ukraine and medical records of patients with CVD, who were prescribed with medicines according to the government program, were used in the study.

Results: according to the method proposed for forecasting the volume of drug reimbursement to patients with CVD under the government program it has been found that Enalapril has the highest indicator – 10916.4 USD thousand in 2019 and 10736.8 USD thousand in 2020. Clopidogrel takes the second position – 12108.13 USD thousand and 11908.24 USD thousand, while Amlodipine occupies the third position – 9105.60 USD thousand and 8955.28 USD thousand.

Among the medicines not included in the government program, but prescribed rather frequently the largest forecasting amount required for reimbursement (in case of inclusion in the program) is 18910.55 USD thousand in 2019 and 18598.36 USD thousand in 2020 for Magnicor, and the least amount is 444.55 USD thousand and 437.22 USD thousand for Acetylsalicylic acid, respectively.

Conclusions. The government program to provide patients with effective and affordable medicines has a significant impact on reforming the healthcare system of Ukraine. The study conducted can be used to expand the government program in the process of formation and distribution of budget funds.


cardiovascular diseases; forecasting; reimbursement; medicines; healthcare

Full Text:



WHO official website. Available at:

World Heart Federation. Available at:

About the approval of the Healthcare Financing Reform Concept (2016). Kabinet Ministriv Ukrainy No. 1013-р. 30.11.2016. Available at: %D1 %80

Government program ”Available medicines”. Available at:

USAID “Safe and affordable drugs” project. Apteka, 16 (1137). Available at:

US Centers for Disease Control and Prevention. Available at:

Cochrane Collaboration. Available at:

State Statistics Service of Ukraine. Available at:

Official website of the Ministry of Health of Ukraine. Available at:

Medical home model reimbursement rates for ihs& tribal health facilities in Arizona (2011). Available at:

Medicaid Drug Rebate Program. Available at:

Yakovenko, E. P., Krasnolobova, L. P., Yakovenko, A. V., Agafonova, N. A., Ivanov, A. N., Bogomolova E. A. et. al. (2013). Effect of acetylsalicylic acid formulations on morpho-functional status of gastric mucosa in elderly cardiac patients. Heart: a journal for practicing physicians, 3, 145–150.

The National Center for Biotechnology Information. Available at:

Franken, M. G. (2014). Decision making in drug reimbursement. Erasmus University Rotterdam. Available at:

Johnson, P. E. (2008). Pharmaceutical reimbursement: An overview. American Journal of Health-System Pharmacy, 65 (2), 4–10. doi:

Hu, J., Mossialos, E. (2016). Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts. Health Policy, 120 (5), 519–534. doi:

Fifer, R. (2016). Health Care Economics: The Real Source of Reimbursement Problems. CCC-A American Speech-Language-Hearing Association (ASHA).

Husereau, D., Dempster, W., Blanchard, A., Chambers, J. (2014). Evolution of Drug Reimbursement in Canada: The Pan-Canadian Pharmaceutical Alliance for New Drugs. Value in Health, 17 (8), 888–894. doi:

Konstam, M. A. (2018). The future of cardiovascular care: from affordable care to the academic medical center. Transactions of the American Clinical and Climatological Association, 129, 301–311.

Konstam, M. A., Hill, J. A., Kovacs, R. J., Harrington, R. A., Arrighi, J. A., Khera, A. (2017). The Academic Medical System. Journal of the American College of Cardiology, 69 (10), 1305–1312. doi:



  • There are currently no refbacks.

Copyright (c) 2019 Alla Nemchenko, Viktoriya Nazarkina, Yuliia Kurylenko

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2504-5679 (Online), ISSN 2504-5660 (Print)